Akèy › Timè nan sèvo › North Carolina
Etid klinik pou Timè nan sèvo nan North Carolina
20 etid pou Timè nan sèvo ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Duke University School of Medicine, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0100, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07492680A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Wake Forest University at Clemmons, Clemmons
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- ak 4 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04511013A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Duke Cancer Institute, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Duke University, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07428616Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05609994Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Atrium Health Wake Forest Baptist, Winston-Salem
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Aug 19, 2026 · NCT05317858MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT04073966B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy
- Duke University Medical Center, Durham
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT07271966Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Vidant Heath - ECU Medical Center, Greenville
- Atlantic Brain & Spine, Wilmington
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 22, 2026 · NCT04427384Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 17, 2026 · NCT05692635REMASTer: REcurrent Brain Metastases After SRS Trial
- Wake Forest Baptist Medical Center, Winston-Salem
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT05124912Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Cone Health Cancer Center, Greensboro
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 9, 2026 · NCT03550391Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
- Lineberger Comprehensive Cancer Center, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05366179Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- Duke University, Durham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06625684Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
- Duke Cancer Center, Durham
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 19, 2025 · NCT05480644APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 27, 2025 · NCT03175224Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.